Eric Easom, Chief Executive Officer at AN2 Therapeutics, Inc. (ANTX), sold 5,554 shares at $20.09 ($112K) on 2024-01-02, disclosed to the SEC on 2024-01-04.
Scheduled sale ($112k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.09 | 2,777 | $56K | 50.0% |
| 2 | $20.09 | 2,777 | $56K | 50.0% |
| Total | $20.09 avg | 5,554 | $112K | 100% |
| Filing → |
| ANTX | BUY | 2023-05-15 | $54K | — | Filing → |
| ANTX | SELL | 2022-11-14 | $136K | — | Filing → |
| ANTX | SELL | 2022-11-09 | $426K | — | Filing → |